Open Save New
FeedNavigator / National Library of Health Sciences
 
  
Tutkijat / Oulu
AddAla-Kokko, L.
AddAla-Kokko, T(ero)
AddAla-Korpela, M(ika)
AddAlahuhta, S.
AddAlén, M(arkku)
AddAntikainen, R.
AddAnttonen, V(uokko)
AddBiancari, F(austo)
AddBloigu, R(isto)
AddEskelinen, S.
AddFlinkkilä, T(apio)
AddHakkola, J.
AddHallman, M.
AddHartikainen, A(nna)-L(iisa)
AddHausen, H.
AddHautala, N(ina)
AddHautala, T(imo)
AddHeape, A.
AddHerzig, K(arl)-H(einz)
AddHillbom, M.
AddHiltunen, J.K.
AddHörkko, S.
AddHuikuri, H(eikki)
AddHukkanen J(anne)
AddIgnatius, J.
AddIsohanni, M.
AddJaakkola, J.
AddJaakkola, M(aritta) S.
AddJaakola, V-P.
AddJämsä, T(imo)
AddJanhonen, S.
AddJartti, T(uomas)
AddJärvelin, M(arjo)-R(iitta)
AddJokelainen, J(ari)
AddJuffer, A(ndré) H.
AddJunttila, J(uhani)
AddJuvonen, T.
AddKaarteenaho, R(iitta)
AddKajantie, E(ero)*(THL/OY)
AddKarppinen (Koivunen), P(eppi)
AddKarppinen, J(aro)
AddKarttunen, T.J.
AddKeinänen-Kiukaanniemi, S(irkka)
AddKerkelä, R(isto)
AddKesäniemi, Y(rjö) A(ntero)
AddKettunen, J(ohannes)
AddKietzmann, T(homas).
AddKivirikko, K.I.
AddKnuuttila, M.
AddKoivukangas, J.
AddKursula, P(etri)
AddKyngäs, H.
AddLarivaara, P.
AddLarmas, M.
AddLehenkari, P(etri)
AddLehtiö, L(ari)
AddLeppilahti, J.
AddLuukinen, H.
AddMainio A
AddMajamaa, K.
AddMäki, P(irjo)
AddMäkikallio, T(imo) H.
AddMännikkö, M(inna)
AddManninen, A(ki).
AddMartikainen, H(annu)
AddMiettunen, J(ouko)
AddMyllyharju, J(ohanna)
AddMyllylä, R.
AddMyllylä, V.
AddNäyhä, S(imo)
AddNeubauer, P.
AddNieminen, M(iika) T.
AddNieminen, P(entti)
AddNiinimäki, J(aakko)
AddOhukainen, P(auli)
AddOikarinen, A.
AddOikarinen, K.
AddPelkonen, O(lavi)
AddPetäjä-Repo, U.E.
AddPihlajaniemi, T(aina)
AddPirttiniemi, P(ertti)
AddPuistola, U(lla)
AddRajaniemi, H.J.
AddRäsänen, P.
AddRaustia, A.
AddRemes, A(nne)
AddRisteli, J.
AddRistiniemi, J.
AddRuddock, L.W.
AddRuokonen, A.
AddRyynänen, M.
AddSaarakkala, S.
AddSaari, A.
AddSalo, T(uula)
AddSándor, G(eorge) K.
AddSavolainen, E-R.
AddSavolainen, M.J.
AddSavolainen, O.
AddSillanpää, M(ikko).
AddSoininen, R.
AddSorri, M.
AddTaanila, A.
AddTapiainen, T(erhi)
AddTervonen, O(smo)
AddTimonen, M(arkku)
AddTurpeenniemi-Hujanen, T.
AddTuukkanen, J(uha)
AddTuulonen, A.
AddUhari, M.
AddUkkola, O(lavi)
AddUusimaa, J.
AddVainio, O.
AddVainio, S.
AddVäyrynen, J(uha) P.
AddVeijola, J(uha)
AddVeijola, R(iitta)
AddVirokannas, H.
AddVoipio, H(anna)-M(arja)
AddVuolteenaho, O.
AddWeckström, M.
AddWei, GH.
AddWierenga, R.K.
AddWinqvist, R(obert)
AddYlänne, J.
AddYlitalo, K(ari)

Scholar Chart >>



»My Articles

»Latest Feeds

»Popular Feeds
Search Feed Catalog by Name:
Critique of the "Comment" etitled "Pyrethroid exposure: not so harmless after all" by Demeneix et al. (2020) published in The Lancet Diabetes Endocrinology.Pelkonen, O(lavi)330 dayssaveRefWorks
Statement on the translocation potential by Pseudomonas chlororaphis MA342 in plants after seed treatment of cereals and peas and assessment of the risk to humans.Pelkonen, O(lavi)396 dayssaveRefWorks
Inhibition and induction of CYP enzymes in humans: an update.Pelkonen, O(lavi)400 dayssaveRefWorks
CYP-associated drug-drug interactions: A mission accomplished?Pelkonen, O(lavi)422 dayssaveRefWorks
Scientific Opinion of the Scientific Panel on Plant Protection Products and their Residues (PPR Panel) on the genotoxic potential of triazine amine (metabolite common to several sulfonylurea active substances).Pelkonen, O(lavi)456 dayssaveRefWorks
Scientific statement on the coverage of bats by the current pesticide risk assessment for birds and mammals.Pelkonen, O(lavi)515 dayssaveRefWorks
Scientific Opinion on the setting of health-based reference values for metabolites of the active substance terbuthylazine.Pelkonen, O(lavi)515 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)532 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity: how to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)542 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)571 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)575 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)578 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)578 dayssaveRefWorks
Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?Pelkonen, O(lavi)578 dayssaveRefWorks
Validation of in vitro methods for human cytochrome P450 enzyme induction: Outcome of a multi-laboratory study.Pelkonen, O(lavi)914 dayssaveRefWorks
Integration of epidemiological findings with mechanistic evidence in regulatory pesticide risk assessment: EFSA experiences.Pelkonen, O(lavi)942 dayssaveRefWorks
Editorial.Pelkonen, O(lavi)1052 dayssaveRefWorks
Establishing a systematic framework to characterise in vitro methods for human hepatic metabolic clearance.Pelkonen, O(lavi)1208 dayssaveRefWorks
Obfuscating Transparency?Pelkonen, O(lavi)1234 dayssaveRefWorks
Toxicology meets Pharmacodynamics and Pharmacokinetics - New Concepts, Models and In Vitro Approaches and Tools.Pelkonen, O(lavi)1255 dayssaveRefWorks
CYP Induction and Xeno-Sensing Receptors PXR, CAR, AHR and PPARα at the Crossroads of Toxicokinetics and Toxicodynamics.Pelkonen, O(lavi)1362 dayssaveRefWorks
Chemical exposure and infant leukaemia: development of an adverse outcome pathway (AOP) for aetiology and risk assessment research.Pelkonen, O(lavi)1652 dayssaveRefWorks
Cardiac safety of ophthalmic timolol.Pelkonen, O(lavi)1869 dayssaveRefWorks
Upholding science in health, safety and environmental risk assessments and regulations.Pelkonen, O(lavi)1902 dayssaveRefWorks
Cardiac safety of ophthalmic timolol.Pelkonen, O(lavi)1932 dayssaveRefWorks
Response to“The Path Forward on Endocrine Disruptors Requires Focus”.Pelkonen, O(lavi)2020 dayssaveRefWorks
Tandem mass spectrometric analysis of S- and N-linked glutathione conjugates of pulegone and menthofuran and identification of P450 enzymes mediating their formation.Pelkonen, O(lavi)2092 dayssaveRefWorks
Metabolism and metabolite profiles in vitro and in vivo of ospemifene in humans and preclinical species.Pelkonen, O(lavi)2207 dayssaveRefWorks
Differentiation-Promoting Medium Additives for Hepatocyte Cultivation and Cryopreservation.Pelkonen, O(lavi)2303 dayssaveRefWorks
Formation of GSH-trapped reactive metabolites in human liver microsomes, S9 fraction, HepaRG-cells, and human hepatocytes.Pelkonen, O(lavi)2306 dayssaveRefWorks
Drug Metabolism - From In Vitro to In Vivo, from Simple to Complex Reflections of the BCPT Nordic Prize 2014 Awardee.Pelkonen, O(lavi)2363 dayssaveRefWorks
Principles of Pharmacology and Toxicology Also Govern Effects of Chemicals on the Endocrine System.Pelkonen, O(lavi)2377 dayssaveRefWorks
Very low mammographic breast density predicts poorer outcome in patients with invasive breast cancer.Pelkonen, O(lavi)2466 dayssaveRefWorks
Biotransformation in vitro: An essential consideration in the quantitative invitro-to-in vivo extrapolation (QIVIVE) of toxicity data.Pelkonen, O(lavi)2558 dayssaveRefWorks
Reactive Metabolites in Early Drug Development: Predictive in Vitro Tools.Pelkonen, O(lavi)2607 dayssaveRefWorks
Why is Research on Herbal Medicinal Products Important and How Can We Improve Its Quality?Pelkonen, O(lavi)2744 dayssaveRefWorks
Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.Pelkonen, O(lavi)2884 dayssaveRefWorks
Human variation and CYP enzyme contribution in benfuracarb metabolism in human in vitro hepatic models.Pelkonen, O(lavi)3006 dayssaveRefWorks
Analytical challenges for conducting rapid metabolism characterization for QIVIVE.Pelkonen, O(lavi)3014 dayssaveRefWorks
Open letter to the European commission: scientifically unfounded precaution drives European commission's recommendations on EDC regulation, while defying common sense, well-established science, and risk assessment principles.Pelkonen, O(lavi)3020 dayssaveRefWorks
Comparative metabolism of benfuracarb in in vitro mammalian hepatic microsomes model and its implications for chemical risk assessment.Pelkonen, O(lavi)3027 dayssaveRefWorks
Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.Pelkonen, O(lavi)3041 dayssaveRefWorks
Estimation of health risk by using toxicokinetic modelling: A case study of polychlorinated biphenyl PCB153.Pelkonen, O(lavi)3042 dayssaveRefWorks
Effects of ospemifene on drug metabolism mediated by cytochrome p450 enzymes in humans in vitro and in vivo.Pelkonen, O(lavi)3054 dayssaveRefWorks
Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.Pelkonen, O(lavi)3059 dayssaveRefWorks
Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene.Pelkonen, O(lavi)3063 dayssaveRefWorks
"Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.''Pelkonen, O(lavi)3063 dayssaveRefWorks
Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.Pelkonen, O(lavi)3069 dayssaveRefWorks
Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.Pelkonen, O(lavi)3070 dayssaveRefWorks
Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations.Pelkonen, O(lavi)3104 dayssaveRefWorks
 XML / RSS feed
report
next »